Episodes

Wednesday Jan 13, 2021
COVID-19, Cystic Fibrosis & Vaccines: Q & A with Richard Moss, MD
Wednesday Jan 13, 2021
Wednesday Jan 13, 2021
On January 7, 2021, CFRI hosted a webinar with Dr. Rick Moss, CF clinician and researcher at Stanford. Dr. Moss gave an overview of the current state of the pandemic - including its impact upon those with cystic fibrosis - and answered questions from the CF community with a focus on vaccines.
CF Community Voices is sponsored to date by Chiesi USA.
If you watch this podcast episode, please let us know what you think at https://www.surveymonkey.com/r/TMRP766

Wednesday Jan 13, 2021
COVID-19, Cystic Fibrosis & Vaccines: Q & A with Richard Moss, MD
Wednesday Jan 13, 2021
Wednesday Jan 13, 2021
On January 7, 2021, CFRI hosted a webinar with Dr. Rick Moss, CF clinician and researcher at Stanford. Dr. Moss gave an overview of the current state of the pandemic - including its impact upon those with cystic fibrosis - and answered questions from the CF community with a focus on vaccines.
CF Community Voices is sponsored to date by Chiesi USA.
If you watch this podcast episode, please let us know what you think at https://www.surveymonkey.com/r/TMRP766

Wednesday Dec 09, 2020
A Review of Lenabasum Phase II Clinical Trial Results - James Chmiel, MD, MPH (Audio)
Wednesday Dec 09, 2020
Wednesday Dec 09, 2020
The role of anti-inflammatories in CF care is vital. Lenabasum, Corbus Pharmaceuticals' investigational drug that mimics the effects of endocannabinoids in regulating inflammation, has been tracked through the clinical trial process with tremendous optimism. Dr. Chmiel, Principal Investigator of CF-002 (lenabasum), and Division Chief for Pediatric Pulmonology, Allergy and Sleep Medicine at Indiana University School of Medicine, reviews the results of the recent Phase IIb trial, and its implications for the CF community.
Sponsored by Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, Genentech, and Viatris, with additional support from Corbus Pharmaceuticals.

Wednesday Dec 09, 2020
A Review of Lenabasum Phase II Clinical Trial Results - James Chmiel, MD, MPH
Wednesday Dec 09, 2020
Wednesday Dec 09, 2020
The role of anti-inflammatories in CF care is vital. Lenabasum, Corbus Pharmaceuticals' investigational drug that mimics the effects of endocannabinoids in regulating inflammation, has been tracked through the clinical trial process with tremendous optimism. Dr. Chmiel, Principal Investigator of CF-002 (lenabasum), and Division Chief for Pediatric Pulmonology, Allergy and Sleep Medicine at Indiana University School of Medicine, reviews the results of the recent Phase IIb trial, and its implications for the CF community.
Sponsored by Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, Genentech, and Viatris, with additional support from Corbus Pharmaceuticals.

Thursday Jun 25, 2020
Greet Me Germ Free - The Update
Thursday Jun 25, 2020
Thursday Jun 25, 2020
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, Chiesi USA, and Mylan Pharmaceuticals for their support of these podcasts.

Wednesday Jun 24, 2020
COVID-19 and Cystic Fibrosis: Q&A Session #11 with Rick Moss, MD - June 24, 2020
Wednesday Jun 24, 2020
Wednesday Jun 24, 2020
Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past week related to antibody tests, impacts on those with CF, and much more. This session was recorded on June 24, 2020.
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, and Chiesi USA for their support of these podcasts.
Track: Woods Artist: Federico Fabbiano Music provided by Oak Studios https://youtu.be/eAiAlg22gqQ

Wednesday May 27, 2020
COVID-19 and Cystic Fibrosis: Q & A #10 with Rick Moss, MD - May 27, 2020
Wednesday May 27, 2020
Wednesday May 27, 2020
Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past week related to antibody tests, impacts on those with CF, and much more. This final session was recorded on May 27, 2020.
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, and Chiesi USA for their support of these podcasts.
Track: Woods Artist: Federico Fabbiano Music provided by Oak Studios https://youtu.be/eAiAlg22gqQ

Wednesday May 20, 2020
COVID-19 and Cystic Fibrosis: Q & A #9 with Rick Moss, MD - May 20, 2020
Wednesday May 20, 2020
Wednesday May 20, 2020
Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past week related to antibody tests, impacts on those with CF, and much more. Please feel free to submit additional questions by email to sreveles@cfri.org. This session was recorded on May 20, 2020.
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, and Chiesi USA for their support of these podcasts.
Track: Woods Artist: Federico Fabbiano Music provided by Oak Studios https://youtu.be/eAiAlg22gqQ

Wednesday May 13, 2020
COVID-19 and Cystic Fibrosis: Q&A #8 with Rick Moss, MD - May 13, 2020
Wednesday May 13, 2020
Wednesday May 13, 2020
Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past week related to antibody tests, impacts on those with CF, and much more. Please feel free to submit additional questions by email to sreveles@cfri.org. This most recent session was recorded on May 13, 2020.
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, and Chiesi USA for their support of these podcasts.
Track: Woods Artist: Federico Fabbiano Music provided by Oak Studios https://youtu.be/eAiAlg22gqQ

Wednesday May 06, 2020
COVID-19 & Cystic Fibrosis: Q&A Session #7 with Rick Moss, MD - May 6, 2020
Wednesday May 06, 2020
Wednesday May 06, 2020
Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past week related to antibody tests, impacts on those with CF, and much more. Dr. Moss has generously offered to continue these Q&A sessions to keep us informed. Please feel free to submit additional questions by email to cfri@cfri.org. This most recent session was recorded on May 6, 2020.
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, and Chiesi USA for their support of these podcasts.